Immunocore (IMCR) Revenue & Revenue Breakdown
Immunocore Revenue Highlights
Latest Revenue (Y)
$310.20M
Latest Revenue (Q)
$75.40M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
UNITED STATES
Immunocore Revenue by Period
Immunocore Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $310.20M | 24.37% |
| 2023-12-31 | $249.43M | 73.53% |
| 2022-12-31 | $143.74M | 441.99% |
| 2021-12-31 | $26.52M | -11.93% |
| 2020-12-31 | $30.11M | 17.32% |
| 2019-12-31 | $25.67M | 8.52% |
| 2018-12-31 | $23.65M | - |
Immunocore generated $310.20M in revenue during NA 2024, up 24.37% compared to the previous quarter, and up 1208.47% compared to the same period a year ago.
Immunocore Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $75.40M | 6.95% |
| 2024-03-31 | $70.50M | -33.26% |
| 2023-12-31 | $105.64M | 68.68% |
| 2023-09-30 | $62.62M | 3.54% |
| 2023-06-30 | $60.48M | 9.86% |
| 2023-03-31 | $55.06M | 14.55% |
| 2022-12-31 | $48.06M | 16.66% |
| 2022-09-30 | $41.20M | 28.74% |
| 2022-06-30 | $32.00M | 42.40% |
| 2022-03-31 | $22.47M | 240.88% |
| 2021-12-31 | $6.59M | 11.29% |
| 2021-09-30 | $5.92M | 3.33% |
| 2021-06-30 | $5.73M | -30.68% |
| 2021-03-31 | $8.27M | 11.46% |
| 2020-12-31 | $7.42M | 11.55% |
| 2020-09-30 | $6.65M | -14.58% |
| 2020-06-30 | $7.79M | -5.67% |
| 2020-03-31 | $8.26M | 46.31% |
| 2019-12-31 | $5.64M | - |
Immunocore generated $75.40M in revenue during Q2 2024, up 6.95% compared to the previous quarter, and up 136.95% compared to the same period a year ago.
Immunocore Revenue Breakdown
Immunocore Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Collaboration Revenue | $213.00K | - | - | - | - |
| Product Revenue | - | $238.74M | - | - | - |
| Genentech | - | - | $2.48M | $17.43M | $20.24M |
| Eli Lilly | - | - | - | - | $3.52M |
| GlaxoSmithKline | - | - | - | $6.08M | $6.36M |
| Med Immune | - | - | - | - | - |
Immunocore's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 |
|---|---|---|---|
| Collaboration Revenue | $53.00K | $160.00K | - |
| Product | - | $80.25M | - |
| Product Revenue | - | - | $70.34M |
Immunocore's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (100.00%).
Immunocore Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Europe | $73.22M | $67.63M | $35.49M | $3.01M | - |
| International | $10.08M | - | - | - | - |
| UNITED STATES | $226.69M | $169.79M | - | - | - |
| Rest of World | - | $3.60M | $871.00K | - | - |
| United States | - | - | $80.45M | $17.43M | $23.76M |
| UK | - | - | - | $6.08M | $6.36M |
Immunocore's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (73.13%), Europe (23.62%), and International (3.25%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Mar 24 |
|---|---|---|---|
| UNITED STATES | $119.39M | $57.27M | $50.03M |
| International | $8.20M | $1.88M | - |
| Europe | $33.17M | $21.10M | $18.95M |
| Rest of World | - | - | $1.36M |
Immunocore's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (74.27%), Europe (20.64%), and International (5.10%).
Immunocore Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MIRM | Mirum Pharmaceuticals | $336.89M | $77.88M |
| IMCR | Immunocore | $310.20M | $75.40M |
| ACLX | Arcellx | $107.94M | $26.03M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
| LYRA | Lyra Therapeutics | $1.53M | $195.00K |
| DSGN | Design Therapeutics | - | - |
| VTYX | Ventyx Biosciences | - | - |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| KALV | KalVista Pharmaceuticals | - | - |
| VRDN | Viridian Therapeutics | - | $86.00K |
| ERAS | Erasca | - | - |
| LRMR | Larimar Therapeutics | - | - |